DTRA Awards $3.3 M Contract to Psioxus Therapeutics
News Jan 18, 2013
PsiOxus will use the company’s proprietary PolyMAP technology to help improve the safety and efficacy of two vaccines candidates: the recombinant Protective Antigen (rPA) for Anthrax and the Venezuelan Equine Encephalopathy Virus (VEEV). PolyMAP is an immunotherapeutic platform that combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines.
“We are honoured to have received this contract from the DTRA and excited at the prospect of helping to improve the safety and efficacy of these two very important vaccine candidates using the PolyMAP technology,” said Dr. John Beadle, CEO of PsiOxus Therapeutics. “Adjuvant platforms are key to innovating and growing the global vaccine market, and we are confident that our immunotherapeutic platform PolyMAP, along with our oncolytic vaccines expertise and team of renowned scientists, will play a significant and long-term role in the future of the industry.”
The contract will support work over a three-year period in the US, as well as in the company’s new state-of-the-art laboratory in Oxford, which has been designed and equipped as a category two laboratory for the handling of live viruses.
The global market for Human Vaccines is forecast to reach US$32.21 billion by the year 2017 1, with key factors such as the growing pediatric population, world travel, and addiction driving market growth. The potential for significant growth and uptake of therapeutic vaccines is expected to further add to this significant growth potential in the longer term.